HUP0103100A2 - Immunogén béta-propionamido-kötött pliszacharid-fehérje konjugátum, mely N-akriloilezett poliszacharid felhasználásával vakcinaként alkalmazható - Google Patents
Immunogén béta-propionamido-kötött pliszacharid-fehérje konjugátum, mely N-akriloilezett poliszacharid felhasználásával vakcinaként alkalmazhatóInfo
- Publication number
- HUP0103100A2 HUP0103100A2 HU0103100A HUP0103100A HUP0103100A2 HU P0103100 A2 HUP0103100 A2 HU P0103100A2 HU 0103100 A HU0103100 A HU 0103100A HU P0103100 A HUP0103100 A HU P0103100A HU P0103100 A2 HUP0103100 A2 HU P0103100A2
- Authority
- HU
- Hungary
- Prior art keywords
- propionamido
- polysaccharide
- immunogenic
- linked
- betha
- Prior art date
Links
- 150000004676 glycans Chemical class 0.000 title abstract 5
- 229920001282 polysaccharide Polymers 0.000 title abstract 5
- 239000005017 polysaccharide Substances 0.000 title abstract 5
- 230000002163 immunogen Effects 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 3
- 229920001542 oligosaccharide Polymers 0.000 abstract 2
- 150000002482 oligosaccharides Chemical class 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 1
- 230000021615 conjugation Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
A találmány tárgya új immunogén b-propionamido-kötött poliszacharid-és N-propionamido-kötött oligoszacharid-fehérje konjugátumokbiztosítása és ezen konjugátumok előállítási eljárásai. A konjugációsfolyamat egyszerű, gyors, megismételhető és számos poliszacharid vagyoligoszacharid esetében alkalmazható, melyek baktériumokból,élesztőkből, daganatos sejtekből származnak, vagy melyeket kémiailagszintetizálnak. Ez a találmány a fertőzések vagy daganatok ellenvakcinákat és eljárásokat tesz közzé, melyekhez az immunogén b-propionamido-kötött poliszacharid- és b-propionamido-kötöttoligoszacharid-fehérje konjugátumokat használja fel. Ó
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9712098P | 1998-08-19 | 1998-08-19 | |
US37691199A | 1999-08-18 | 1999-08-18 | |
PCT/US1999/018982 WO2000010599A2 (en) | 1998-08-19 | 1999-08-18 | IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0103100A2 true HUP0103100A2 (hu) | 2001-11-28 |
HUP0103100A3 HUP0103100A3 (en) | 2005-11-28 |
Family
ID=26792625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0103100A HUP0103100A3 (en) | 1998-08-19 | 1999-08-18 | Immunogenic betha-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide |
Country Status (15)
Country | Link |
---|---|
US (1) | US20040213804A1 (hu) |
EP (1) | EP1109576B1 (hu) |
JP (1) | JP2004505885A (hu) |
KR (1) | KR100704826B1 (hu) |
CN (1) | CN1263510C (hu) |
AT (1) | ATE446107T1 (hu) |
AU (1) | AU771330B2 (hu) |
CA (1) | CA2340692A1 (hu) |
CZ (1) | CZ2001622A3 (hu) |
DE (1) | DE69941574D1 (hu) |
HK (1) | HK1041825B (hu) |
HU (1) | HUP0103100A3 (hu) |
NO (1) | NO20010805L (hu) |
NZ (1) | NZ509986A (hu) |
WO (1) | WO2000010599A2 (hu) |
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY125387A (en) | 1999-03-19 | 2006-07-31 | Smithkline Beecham Biologicals S A | Vaccine |
AU5697001A (en) * | 2000-03-31 | 2001-10-15 | Purdue Research Foundation | Method of treatment using ligand-immunogen conjugates |
WO2001098334A2 (en) * | 2000-06-20 | 2001-12-27 | Shire Biochem Inc. | Streptococcus antigens |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
WO2004011027A1 (en) * | 2002-07-30 | 2004-02-05 | Baxter International Inc. | Chimeric multivalent polysaccharide conjugate vaccines |
SI1549338T1 (sl) | 2002-10-11 | 2011-04-29 | Novartis Vaccines & Diagnostic | Polipeptidna cepiva za ĺ iroko zaĺ äśito pred hipervirulentnimi miningokoknimi rodovi |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
ES2411080T3 (es) | 2003-01-30 | 2013-07-04 | Novartis Ag | Vacunas inyectables contra múltiples serogrupos de meningococos |
MXPA05014015A (es) * | 2003-06-23 | 2006-03-17 | Baxter Int | Vacunas contra grupo y nisseria meningitidis y combinaciones meningococales del mismo. |
PL1961426T3 (pl) | 2003-10-02 | 2012-03-30 | Gsk Vaccines S R L | Skojarzone szczepionki przeciwko zapaleniu opon mózgowo-rdzeniowych |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
US7422755B2 (en) * | 2004-01-15 | 2008-09-09 | The United States Of America As Represented By The Department Of Health And Human Services | Antimultiorganism glycoconjugate vaccine |
GB0406013D0 (en) | 2004-03-17 | 2004-04-21 | Chiron Srl | Analysis of saccharide vaccines without interference |
SI1740217T1 (sl) | 2004-04-30 | 2011-10-28 | Novartis Ag | Konjugirano meningokokno cepljenje |
GB0500787D0 (en) | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
GB0409745D0 (en) | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
GB0411387D0 (en) | 2004-05-21 | 2004-06-23 | Chiron Srl | Analysis of saccharide length |
GB0413868D0 (en) | 2004-06-21 | 2004-07-21 | Chiron Srl | Dimensional anlaysis of saccharide conjugates |
GB0502095D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
NZ564606A (en) | 2005-06-27 | 2010-10-29 | Glaxosmithkline Biolog Sa | Immunogenic composition comprising atleast two N. meningitidis capsular polysaccharides conjugated through a linker protein |
EP2333549A3 (en) * | 2005-09-05 | 2011-11-02 | GlaxoSmithKline Biologicals s.a. | Serum bactericidal assay for n. meningitidis specific antisera |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
NO346529B1 (no) | 2005-12-22 | 2022-09-26 | Glaxosmithkline Biologicals Sa | Bruk av et immunogenpreparat for småbarn, omfattende 22F sakkaridkonjugat |
WO2007084856A2 (en) * | 2006-01-13 | 2007-07-26 | Baxter International Inc. | Method for purifying polysaccharides |
WO2007092299A2 (en) | 2006-02-03 | 2007-08-16 | Purdue Research Foundation | Targeted conjugates and radiation |
PL2004225T3 (pl) | 2006-03-22 | 2012-09-28 | Novartis Ag | Schematy immunizacji koniugatami meningokokowymi |
GB0605757D0 (en) | 2006-03-22 | 2006-05-03 | Chiron Srl | Separation of conjugated and unconjugated components |
GB0612854D0 (en) | 2006-06-28 | 2006-08-09 | Novartis Ag | Saccharide analysis |
AU2007293672B2 (en) | 2006-09-07 | 2013-06-27 | Glaxosmithkline Biologicals S.A. | Vaccine |
GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
DK2457920T3 (en) * | 2007-01-18 | 2018-01-22 | Genzyme Corp | Oligosaccharides comprising an amino oxy group and conjugates thereof |
KR20100017569A (ko) | 2007-05-02 | 2010-02-16 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
ES2621359T3 (es) * | 2007-06-20 | 2017-07-03 | Pfizer Ireland Pharmaceuticals | Polisacáridos modificados para vacunas conjugadas |
CN101883583B (zh) | 2007-06-26 | 2017-05-17 | 葛兰素史密丝克莱恩生物有限公司 | 含有肺炎链球菌荚膜多糖缀合物的疫苗 |
GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
DK2200642T3 (da) | 2007-10-19 | 2012-07-16 | Novartis Ag | Meningococvaccinepræparater |
GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
CN102356089B (zh) | 2008-02-21 | 2014-02-19 | 诺华股份有限公司 | 脑膜炎球菌fHBP多肽 |
SI2349520T1 (sl) | 2008-10-27 | 2016-08-31 | Glaxosmithkline Biologicals S.A. | Postopek čiščenja za ogljikohidrat iz Streptococcus skupine A |
GB0822633D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
GB0822634D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Meningitis vaccines |
JP2012512240A (ja) | 2008-12-17 | 2012-05-31 | ノバルティス アーゲー | ヘモグロビン受容体を含む髄膜炎菌ワクチン |
HUE049695T2 (hu) | 2009-03-24 | 2020-10-28 | Glaxosmithkline Biologicals Sa | Adjuváló H meningococcus faktort kötõ fehérje |
WO2010109324A1 (en) | 2009-03-24 | 2010-09-30 | Novartis Ag | Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates |
BRPI1013780B8 (pt) | 2009-04-14 | 2022-10-04 | Novartis Ag | Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica |
US20120135037A1 (en) | 2009-06-01 | 2012-05-31 | Mizel Steven B | Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same |
CA2772104A1 (en) | 2009-08-27 | 2011-03-03 | Novartis Ag | Hybrid polypeptides including meningococcal fhbp sequences |
CN102695523A (zh) | 2009-09-10 | 2012-09-26 | 诺华有限公司 | 针对呼吸道疾病的组合疫苗 |
JP2013506651A (ja) | 2009-09-30 | 2013-02-28 | ノバルティス アーゲー | Staphylococcus.aureus5型および8型莢膜多糖の結合体 |
EP2483390A2 (en) | 2009-09-30 | 2012-08-08 | Novartis AG | Expression of meningococcal fhbp polypeptides |
BR112012010531A2 (pt) | 2009-10-27 | 2019-09-24 | Novartis Ag | "polipeptídeos de modificação meningocócica fhbp" |
GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
GB201003333D0 (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
GB201003922D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Conjugation process |
GB201003924D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Immunogenic composition |
GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
CA2803239A1 (en) | 2010-06-25 | 2011-12-29 | Novartis Ag | Combinations of meningococcal factor h binding proteins |
WO2012072769A1 (en) | 2010-12-01 | 2012-06-07 | Novartis Ag | Pneumococcal rrgb epitopes and clade combinations |
WO2012085668A2 (en) | 2010-12-24 | 2012-06-28 | Novartis Ag | Compounds |
CN102526724B (zh) * | 2011-01-14 | 2015-07-22 | 四川大学 | 氢氧化铝凝胶-多糖复合免疫佐剂及其制备方法和用途 |
ES2681698T3 (es) | 2011-03-02 | 2018-09-14 | Glaxosmithkline Biologicals Sa | Vacunas de combinación con menores dosis de antígeno y/o adyuvante |
GB201103836D0 (en) | 2011-03-07 | 2011-04-20 | Glaxosmithkline Biolog Sa | Conjugation process |
GB201114923D0 (en) | 2011-08-30 | 2011-10-12 | Novartis Ag | Immunogenic proteins and compositions |
EP3269386B1 (en) | 2011-12-06 | 2022-09-14 | Valneva Austria GmbH | Aluminium compounds for use in therapeutics and vaccines |
GB201121301D0 (en) | 2011-12-12 | 2012-01-25 | Novartis Ag | Method |
JP2015505309A (ja) | 2011-12-29 | 2015-02-19 | ノバルティス アーゲー | 髄膜炎菌h因子結合タンパク質のアジュバントされた組み合わせ |
EP2822584A1 (en) | 2012-03-08 | 2015-01-14 | Novartis AG | Combination vaccines with tlr4 agonists |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
KR101452830B1 (ko) * | 2012-04-06 | 2014-10-21 | 아이진 주식회사 | 두 가지 항암물질을 동시에 제공하는 대장균 균주 |
JP2015518845A (ja) | 2012-05-22 | 2015-07-06 | ノバルティス アーゲー | 髄膜炎菌血清群xコンジュゲート |
EP2892553A1 (en) | 2012-09-06 | 2015-07-15 | Novartis AG | Combination vaccines with serogroup b meningococcus and d/t/p |
CN105307684A (zh) | 2012-10-02 | 2016-02-03 | 葛兰素史密丝克莱恩生物有限公司 | 非直链糖缀合物 |
SG11201502599TA (en) | 2012-10-12 | 2015-05-28 | Glaxosmithkline Biolog Sa | Non-cross-linked acellular pertussis antigens for use in combination vaccines |
RU2018137673A (ru) | 2012-11-30 | 2019-03-22 | Глаксосмитклайн Байолоджикалс Са | Антигены и комбинации антигенов pseudomonas |
WO2014118305A1 (en) | 2013-02-01 | 2014-08-07 | Novartis Ag | Intradermal delivery of immunological compositions comprising toll-like receptor agonists |
JP6387084B2 (ja) | 2013-05-01 | 2018-09-05 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | アポリポタンパク質c−iiiの発現を調節するための組成物および方法 |
EP4098276A1 (en) | 2013-09-08 | 2022-12-07 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
HUE052293T2 (hu) | 2014-02-28 | 2021-04-28 | Glaxosmithkline Biologicals Sa | Módosított fHbp meningococcus-polipeptidek |
US9107906B1 (en) | 2014-10-28 | 2015-08-18 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
EP3034516A1 (en) | 2014-12-19 | 2016-06-22 | Novartis AG | Purification of streptococcal capsular polysaccharide |
GB201518684D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
US10407454B2 (en) | 2016-01-07 | 2019-09-10 | The Board Of Trustees Of The Leland Stanford Junior University | Defined enzymatic synthesis of lipid A analogs |
EP3506933A2 (en) | 2016-09-02 | 2019-07-10 | GlaxoSmithKline Biologicals SA | Vaccines for neisseria gonorrhoeae |
DK3506935T3 (en) | 2016-09-02 | 2024-04-02 | Sanofi Pasteur Inc | Neisseria meningitidis-vaccine |
BE1025162B9 (fr) | 2016-12-06 | 2019-01-07 | Glaxosmithkline Biologicals Sa | Procede de purification pour les polysaccharides capsulaires |
CN118021947A (zh) | 2017-01-31 | 2024-05-14 | 辉瑞大药厂 | 脑膜炎奈瑟菌组合物及其使用方法 |
US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
US20200377620A1 (en) * | 2017-12-19 | 2020-12-03 | The Governors Of The University Of Alberta | Clostridium perfringens surface glycans and uses thereof |
EP3607967A1 (en) | 2018-08-09 | 2020-02-12 | GlaxoSmithKline Biologicals S.A. | Modified meningococcal fhbp polypeptides |
WO2020165711A1 (en) | 2019-02-11 | 2020-08-20 | Pfizer Inc. | Neisseria meningitidiscompositions and methods thereof |
JP7239509B6 (ja) | 2019-02-22 | 2023-03-28 | ファイザー・インク | 細菌多糖類を精製するための方法 |
JOP20200214A1 (ar) | 2019-09-03 | 2021-03-03 | Serum Institute Of India Pvt Ltd | تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها |
CA3155669A1 (en) | 2019-09-27 | 2021-04-01 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
EP3799884A1 (en) | 2019-10-01 | 2021-04-07 | GlaxoSmithKline Biologicals S.A. | Immunogenic compositions |
US20230085173A1 (en) | 2020-02-21 | 2023-03-16 | Pfizer Inc. | Purification of saccharides |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
JP2023546446A (ja) | 2020-10-22 | 2023-11-02 | ファイザー・インク | 細菌多糖を精製する方法 |
GB202208093D0 (en) | 2022-06-01 | 2022-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
GB202208089D0 (en) | 2022-06-01 | 2022-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
GB202215414D0 (en) | 2022-10-18 | 2022-11-30 | Glaxosmithkline Biologicals Sa | Vaccine |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4057685A (en) * | 1972-02-02 | 1977-11-08 | Abbott Laboratories | Chemically modified endotoxin immunizing agent |
US4356170A (en) * | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
US4673574A (en) * | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
US4902506A (en) * | 1983-07-05 | 1990-02-20 | The University Of Rochester | Immunogenic conjugates |
US4619828A (en) * | 1982-07-06 | 1986-10-28 | Connaught Laboratories, Inc. | Polysaccharide exotoxoid conjugate vaccines |
US4459286A (en) * | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
US4663160A (en) * | 1983-03-14 | 1987-05-05 | Miles Laboratories, Inc. | Vaccines for gram-negative bacteria |
US4761283A (en) * | 1983-07-05 | 1988-08-02 | The University Of Rochester | Immunogenic conjugates |
US4808700A (en) * | 1984-07-09 | 1989-02-28 | Praxis Biologics, Inc. | Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers |
IT1187753B (it) * | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
US4727136A (en) * | 1985-10-01 | 1988-02-23 | Canadian Patents And Development Ltd. | Modified meningococcal group B polysaccharide for conjugate vaccine |
US5192540A (en) * | 1988-04-19 | 1993-03-09 | American Cyanamid Company | Haemophilus influenzae type b oxidized polysaccharide-outer membrane protein conjugate vaccine |
NL8802046A (nl) * | 1988-08-18 | 1990-03-16 | Gen Electric | Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen. |
HU218146B (hu) * | 1989-12-14 | 2000-06-28 | National Research Council Of Canada | Továbbfejlesztett meningokokkusz-poliszacharid-konjugátum vakcina |
US5153312A (en) * | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
US5445817A (en) * | 1992-08-21 | 1995-08-29 | The United States Of America As Represented By The Department Of Health And Human Services | Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines |
US5554730A (en) * | 1993-03-09 | 1996-09-10 | Middlesex Sciences, Inc. | Method and kit for making a polysaccharide-protein conjugate |
US5439808A (en) * | 1993-07-23 | 1995-08-08 | North American Vaccine, Inc. | Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis |
US5780606A (en) * | 1995-06-07 | 1998-07-14 | Connaught Laboratories Limited | Neisseria meningitidis capsular polysaccharide conjugates |
US5811102A (en) * | 1995-06-07 | 1998-09-22 | National Research Council Of Canada | Modified meningococcal polysaccharide conjugate vaccines |
-
1999
- 1999-08-18 AU AU57800/99A patent/AU771330B2/en not_active Ceased
- 1999-08-18 NZ NZ509986A patent/NZ509986A/en unknown
- 1999-08-18 CZ CZ2001622A patent/CZ2001622A3/cs unknown
- 1999-08-18 EP EP99945115A patent/EP1109576B1/en not_active Expired - Lifetime
- 1999-08-18 JP JP2000565919A patent/JP2004505885A/ja active Pending
- 1999-08-18 WO PCT/US1999/018982 patent/WO2000010599A2/en active IP Right Grant
- 1999-08-18 DE DE69941574T patent/DE69941574D1/de not_active Expired - Lifetime
- 1999-08-18 CN CNB998121703A patent/CN1263510C/zh not_active Expired - Fee Related
- 1999-08-18 HU HU0103100A patent/HUP0103100A3/hu unknown
- 1999-08-18 KR KR1020017002108A patent/KR100704826B1/ko not_active IP Right Cessation
- 1999-08-18 AT AT99945115T patent/ATE446107T1/de not_active IP Right Cessation
- 1999-08-18 CA CA002340692A patent/CA2340692A1/en not_active Abandoned
-
2001
- 2001-02-16 NO NO20010805A patent/NO20010805L/no not_active Application Discontinuation
-
2002
- 2002-05-16 HK HK02103707.6A patent/HK1041825B/zh not_active IP Right Cessation
-
2004
- 2004-01-20 US US10/761,498 patent/US20040213804A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2000010599A8 (en) | 2000-08-10 |
CZ2001622A3 (cs) | 2002-01-16 |
AU771330B2 (en) | 2004-03-18 |
NO20010805D0 (no) | 2001-02-16 |
WO2000010599A3 (en) | 2000-06-22 |
CN1263510C (zh) | 2006-07-12 |
ATE446107T1 (de) | 2009-11-15 |
CN1323221A (zh) | 2001-11-21 |
US20040213804A1 (en) | 2004-10-28 |
DE69941574D1 (de) | 2009-12-03 |
HK1041825B (zh) | 2007-02-23 |
CA2340692A1 (en) | 2000-03-02 |
NZ509986A (en) | 2003-10-31 |
NO20010805L (no) | 2001-04-03 |
EP1109576B1 (en) | 2009-10-21 |
AU5780099A (en) | 2000-03-14 |
KR100704826B1 (ko) | 2007-04-09 |
EP1109576A2 (en) | 2001-06-27 |
HUP0103100A3 (en) | 2005-11-28 |
KR20010072776A (ko) | 2001-07-31 |
HK1041825A1 (en) | 2002-07-26 |
JP2004505885A (ja) | 2004-02-26 |
WO2000010599A2 (en) | 2000-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0103100A2 (hu) | Immunogén béta-propionamido-kötött pliszacharid-fehérje konjugátum, mely N-akriloilezett poliszacharid felhasználásával vakcinaként alkalmazható | |
AR022963A1 (es) | Vacuna | |
DK1187629T3 (da) | Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid | |
CY1110820T1 (el) | Εμβολια συνδυασμου για neisseria meningitidis | |
EA200801367A1 (ru) | Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae | |
AU2002305099A1 (en) | Fatty alcohol drug conjugates | |
NZ514228A (en) | Method of Expressing Antigens on the Surface of Antigen Presenting Cells by Photochemical Internalisation | |
CA2253632A1 (en) | Compositions and methods for treating cancers and pathogen infections using antigen-presenting cells loaded with rna | |
WO2005086612A3 (en) | Fluorinated carbohydrate conjugates | |
WO2001034801A3 (en) | Recombinant gelatin in vaccines | |
IL136125A0 (en) | Antigenic group b streptococcus type ii and type iii polysaccharide fragments having a 2, 5-anhydro-d-mannose terminal structure and conjugate vaccine thereof | |
HUP0101749A2 (hu) | Készítmények PEG-interferon-alfa-konjugátumok védelmére és eljárás ilyen készítmények előállítására | |
SE9904581D0 (sv) | A novel helicobacter pylori-binding substance and use thereof | |
ATE304709T1 (de) | Substanzen mit verzweigten linkermolekülen | |
WO2000061766A3 (en) | Telomerase-specific cancer vaccine | |
WO2023028165A3 (en) | Tumor-associated calcium signal transducer 2 (tacstd2) antibody-maytansine conjugates and methods of use thereof | |
NO20020615L (no) | Vaksine | |
TR200001682T2 (tr) | Değiştirilmiş biyolojik tanınma gösteren değiştirilmiş polisakaridler | |
AU1594897A (en) | Solid instant-release forms of administration and process for producing the same | |
MY127452A (en) | Vaccines. | |
ID28174A (id) | Turunan 5-imino-13-deoksi antrasiklin, penggunaannya, dan proses pembuatannya | |
CO5241277A1 (es) | Vacuna | |
UA33502A (uk) | Спосіб виготовлення інактивованої вакцини проти сальмонельозів тварин |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |